FT. LAUDERDALE, Fla., Aug. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that the company has acquired the EDC assets of UK based, clinical software provider, Logos Technologies, Ltd. The acquisition will be operated by OmniComm's UK subsidiary, OmniComm Ltd.
Logos' exceptional software is used to collect clinical trial data gathered while conducting Phase I clinical trials. Phase I clinical trials are the first stage of the US or International regulatory approval process, in order to get new drugs and medical devices to the marketplace. The Logos software complements OmniComm's TrialMaster(R) software, which is primarily used in later stage clinical trials. The Logos products cover all aspects of the Phase I process from subject recruitment and clinical workflow management to laboratory sample management. Regular EDC solutions for later stage trials do not include a pro-active data collection system, which is imperative for the very time-controlled data collection during many early stage clinical studies. There are only 3 commonly known Phase I EDC systems in the world that are capable of demonstrating this functionality.
"We look forward to becoming part of OmniComm," said Simon Kemp, Logos Technology Ltd.'s Managing Director. "OmniComm's team of industry professionals was a key factor in our decision making process. We have worked closely with OmniComm in the past with several joint clients and see this as an opportunity to enhance and fully integrate the Logos products with OmniComm's eClinical solutions. Our clients, which include Top 10 Pharmaceutical, leading Academic and Clinical Research Organizations, will also benefit from working with a larger global company like OmniComm. "
"We are pleased to add the Logos products and operations to the OmniComm
|SOURCE OmniComm Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved